Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Eledon Pharmaceuticals, Inc. (ELDN) had Income from Continuous Operations of $-10.45M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-10.45M |
|
-- |
|
-- |
|
$21.48M |
|
$-21.48M |
|
$11.07M |
|
$-10.41M |
|
$-10.41M |
|
$-10.45M |
|
|
Income from Continuous Operations |
$-10.45M |
$-10.45M |
|
$-10.45M |
|
$-21.48M |
|
$-21.48M |
|
81.84M |
|
81.84M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$135.69M |
|
-- |
|
$33.32M |
|
$169.01M |
|
$18.34M |
|
-- |
|
$13.89M |
|
$32.23M |
|
$81.08M |
|
$136.78M |
|
$136.78M |
|
75.43M |
|
| Cash Flow Statement Financials | |
$-62.34M |
|
$10.79M |
|
$53.81M |
|
$20.55M |
|
$22.81M |
|
$2.26M |
|
$10.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-62.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.88% |
|
-7.64% |
|
-6.18% |
|
-7.64% |
|
$1.81 |
|
$-0.76 |
|
$-0.76 |
|